According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial."
New Delhi [India], March 3 (ANI): Phase three results of the COVAXIN, a vaccine against COVID-19 which has been developed by Indian Council of Medical Research (ICMR) in partnership with Bharat Biotech International Limited (BBIL), has shown an interim vaccine efficacy of 81 per cent in p